Market news
On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company’s own guidance range and climbed 9.7% from the prior quarter. But look past the top […]
Detailed price information for Orasure Tech Inc (OSUR-Q) from The Globe and Mail including charting and trades.
Motley Fool Press Release.
Detailed price information for Orasure Tech Inc (OSUR-Q) from The Globe and Mail including charting and trades.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026. “Our Q2 results demonstrate continued progress in our return-to-growth trajectory, with revenue of $30.6 million, up 9.7% sequentially and above our guidance range, along with solid gross margin improvement,” said Carrie Eglinton Manner, Pres
BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Ple
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.BETHLEHEM, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its second generation
This is the newest page. Registered accounts read further back.